Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2009-08-12
2010-10-12
Carr, Deborah D (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S560000, C554S213000
Reexamination Certificate
active
07812054
ABSTRACT:
This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.
REFERENCES:
patent: 5441951 (1995-08-01), Serhan
patent: 5648512 (1997-07-01), Serhan
patent: 5650435 (1997-07-01), Madara et al.
patent: 5998487 (1999-12-01), Brahms et al.
patent: 6048897 (2000-04-01), Serhan
patent: 6316648 (2001-11-01), Serhan
patent: 6569075 (2003-05-01), Serhan
patent: 6620919 (2003-09-01), Serhan
patent: 6635776 (2003-10-01), Serhan
patent: 6653493 (2003-11-01), Serhan
patent: 6670396 (2003-12-01), Serhan et al.
patent: 6750360 (2004-06-01), Serhan
patent: 6887901 (2005-05-01), Serhan
patent: 2001/0023500 (2001-09-01), Serhan
patent: 2001/0031882 (2001-10-01), Serhan
patent: 2002/0010351 (2002-01-01), Serhan
patent: 2002/0045579 (2002-04-01), Madara et al.
patent: 2002/0055538 (2002-05-01), Serhan et al.
patent: 2002/0082435 (2002-06-01), Serhan
patent: 2002/0091279 (2002-07-01), Serhan
patent: 2002/0094549 (2002-07-01), Serhan et al.
patent: 2002/0107289 (2002-08-01), Serhan
patent: 2002/0111505 (2002-08-01), Serhan
patent: 2002/0120013 (2002-08-01), Serhan
patent: 2002/0132847 (2002-09-01), Serhan
patent: 2002/0143069 (2002-10-01), Serhan
patent: 2002/0193431 (2002-12-01), Serhan et al.
patent: 2003/0032827 (2003-02-01), Serhan
patent: 2003/0055275 (2003-03-01), Serhan
patent: 2003/0060512 (2003-03-01), Madara et al.
patent: 2003/0069435 (2003-04-01), Serhan
patent: 2003/0134901 (2003-07-01), Serhan
patent: 2003/0166716 (2003-09-01), Serhan et al.
patent: 2003/0191184 (2003-10-01), Serhan et al.
patent: 2003/0191332 (2003-10-01), Serhan
patent: 2003/0195248 (2003-10-01), Serhan et al.
patent: 2004/0019110 (2004-01-01), Van Dyke et al.
patent: 2004/0053998 (2004-03-01), Serhan et al.
patent: 2004/0059144 (2004-03-01), Serhan et al.
patent: 2004/0116408 (2004-06-01), Serhan
patent: 2004/0151712 (2004-08-01), Madara et al.
patent: 2004/0192785 (2004-09-01), Serhan
patent: 2005/0075398 (2005-04-01), Bazan et al.
patent: WO 94 29262 (1994-12-01), None
patent: WO 95 01179 (1995-01-01), None
patent: WO 98 11049 (1998-03-01), None
patent: WO 00 13685 (2000-03-01), None
patent: WO 01 41753 (2001-06-01), None
Bandeira-Melo C, et al., “Cutting Edge: Lipoxin (LX) A4 and Aspirin-Triggered 15-epi-LXA4 Block Allergen-Induced Eosinophil Trafficking,”J Immunol. 164(5): 2267-71,2000.
Chiang N, et al., “Aspirin-Triggered 15-epi-Lipoxin A4 (ATL) Generation by Human Leukocytes and Murine Peritonitis Exudates: Development of a Specific 15-epi-LXA4 ELISA,”J Pharmacol Exp Ther. 287(2): 779-90, 1998.
Clish CB, et al., “Local and Systemic Delivery of a Stable Aspirin-Triggered Lipoxin Prevents Neutrophil Recruitment In Vivo,”Proc Natl Acad Sci U S A. 96(14): 8247-52, 1999.
Filep JG, et al., “Anti-Inflammatory Actions of Lipoxin A(4) Stable Analogs Are Demonstrable in Human Whole Blood: Modulation of Leukocyte Adhesion Molecules and Inhibition of Neutrophil-Endothelial Interactions,” Blood. 94(12): 4132-42, 1999.
Gerwitz AT, et al., “LXA4, Aspirin-Triggered 15-epi-LXA4, and Their Analogs Selectively Downregulate PMN Azurophilic Degranulation,”Am J Physiol. 276(4 Pt 1): C988-94, 1999.
Gronert K, et al., “Identificatin of a Human Enterocyte Lipoxin A4 Receptor That Is Regulated by Interleukin (IL)-13 and Interferon Gamma and Inhibits Tumor Necrosis Factor Alpha-Induced IL-8 Release,”J Exp Med. 187(8): 1285-94, 1998.
Hachicha M, et al., “Lipoxin (LX)A4 and Aspirin-Triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor 1 Alpha-Initiated Neutrophil Responses and Trafficking: Regulators of a Cytokine-Chemokine Axis,”J Exp Med189(12): 1923-30, 1999.
Maddox JF, et al., “Lipoxin A4 Stable Analogs Are Potent Mimetics That Stimulate Human Monocytes and THP-1 Cells Via A G-Protein-Linked Lipoxin A4 Receptor,”J Biol Chem. 272(11): 6972-8, 1997.
Maddox JF, et al., “Lipoxin B4 Regulates Human Monocyte/Neutrophil Adherence and Motility: Design of Stable Lipoxin B4 Analogs With Increased Biologic Activity,”FASEB J.12(6): 487-494, 1998.
Nicolaou KC, et al., “Total Synthesisof Novel Geometric Isomers of Lipoxin A4 and Lipoxin B4,”Journal of Organic Chemistry, vol. 54 (1989), pp. 5527-5535.
Nokami J, et al., “Palladium-catalyzed Coupling Reactions of Bromobenzaldehydes with 3,4-Di(tert-butyldimethylsilyloxy-)1- alken e to (3,4-Dihydroxyalkenyl) benzaldehydes in the Synthesis of Lipoxin Analogoues,”Tetrahedron Letters, vol. 39 (1998), pp. 1005-1008.
Nguyen AM, et al., “Nonsteroidal Anti-Inflammatory Drug Use in Dentistry: Gastrointestinal Implications,”General Dentistry, vol. 47(6), Nov. 1999, pp. 590-596.
Poulot M, et al., “Lipoxin A4 and Aspirin-Triggered 15-epi-LXA4 Inhibit Tumor Necrosis Factor-alpha.-initiated Neutrophil Responses . . . ”Journal of Periodontal Research, vol. 34, No. 7 (1999), pp. 370-373.
Serhan CN, et al., “Aspirin-Triggered 15-epi-Lipoxin A4 and Stable Analogs on Lipoxin A4 Are Potent Inhibitors of Acute Inflammation,”Adv Exp Med Biol. 447: 133-49, 1999.
Serhan CN, et al., “Lipoxin and Aspirin-Triggered 15-epi-Lipoxin Cellular Interactions Anti-Inflammatory Lipid Mediators,”Clin Chem Lab Med. 37(3): 299-309, 1999.
Serhan CN, et al., “Lipoxins, Aspirin-Triggered 15-epi-Lipoxin Stable Analogs and Their Receptors in Anti-Inflammation: A Window for Therapeutic Opportunity,”Ernst Schering Re Found Workshop31:143-85, 2000.
Serhan CN, Lipoxins and Novel Aspirin-Triggered 15-epi-Lipoxins (ATL): A Jungle Serhan et al., “Of Cell-Cell Interactions or a Therapeutic Opportunity?”Prostaglandins. 53(2):107-37, 1997.
Serhan CN, “Design of Lipoxim A4 Stable Analogs . . . ”Biochemistry, vol. 34 (1995), pp. 14609-1415.
Takano T, et al., “Aspirin-Triggered 15-epi-Lipoxin A4 (LXA4) and LXA4 Stable Analogues Are Potent Inhibitors of Acute Inflammation: Evidence for Anti-Inflammatory Receptors,”J Exp Med. 185(9): 1693-704, 1997.
Takano T, et al., “Neutrophil-Mediated Changes in Vascular Permeability Are Inhibited by Topical Application of Aspirin-Triggered 15-epi-Lipoxin A4 and Novel Lipoxin B4 Stable Analogues,”J Clin Invest. 101(4): 819-26, 1998.
Titos E, et al., “Hepatocytes Are a Rich Source of Novel Aspirin-Triggered 15-epi-Lipoxin A(4),”Am J Physiol. 277(5 Pt 1): C870-7, 1999.
International Search Report for PCT/US01/09096 published Sep. 27, 2001 as WO01/070664.
International Preliminary Examination Report for PCT/US01/09096 published Sep. 27, 2001 as WO01/070664.
Petasis Nicos A.
Serhan Charles N.
Van Dyke Thomas E.
Brigham and Women's Hospital, Inc.
Carr Deborah D
Choate Hall & Stewart LLP
Lyon Charles E.
Trustees of Boston University
LandOfFree
Lipoxin analogs and methods for the treatment of periodontal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoxin analogs and methods for the treatment of periodontal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoxin analogs and methods for the treatment of periodontal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202910